AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00614172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy
Description: Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
Study NCT03140163 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ULD-CT
Description: Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
Study NCT03140163 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CXR
Description: Conventional chest radiograph
Study NCT02633943 — intervention group
Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study.
Study NCT04058028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Rozibafusp Alfa will be presented in 5 mL glass vial
Study NCT04058028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Rozibafusp Alfa
Description: Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
Study NCT03751475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Strategy - OptiMA
Description: All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated).
Study NCT03751475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effective nutritional standard strategy
Description: Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up.
Study NCT02108977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoconferencing Genetic Consultation
Description: Patients will travel to CBOC and receive genetic counseling session via videoconferencing
Study NCT02108977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teleconferencing Genetic Consultation
Description: Patients will receive genetic counseling session via telephone (usual treatment)
Study NCT04391842 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 1% Diclofenac patch
Description: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device
Study NCT00848029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent inactivated influenza vaccine
Description: Two doses of monovalent inactivated influenza adjuvanted vaccine
Study NCT00223002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: sample collected at time of procedure and then analysed for bacterial contamination
Study NCT01566422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Description: patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
Study NCT01363284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
Study NCT03314883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-US ARF
Description: Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
Study NCT04690634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy (LSG)
Description: Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
Study NCT04690634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy (LSG)
Description: Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
Study NCT02938338 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery, with an anticipated mean weight loss of 30 kg
Study NCT03635762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be In Charge
Description: comparison of pre and post-program weight and calorie intake
Study NCT02132143 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation
Description: For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
Study NCT02132143 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation
Description: For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
Study NCT01204086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: MEDI5752 IV Every 3 weeks (q3w)
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV Day 1 of each 21-day cycle
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV Days 1 and 8 of each 21-day cycle
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV Day 1 of each 21-day cycle
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: AZD2936 IV
Study NCT01204086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
Study NCT01818973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
Study NCT01818973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
Study NCT01818973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
Study NCT01818973 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
Study NCT01818973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Total Mesorectal Excision (TME)
Study NCT04967105 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
Study NCT00594230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
Study NCT00179803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue.
Study NCT04084730 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
Study NCT02045186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of Oral HPV Infection
Description: Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry.
Study NCT05858866 — intervention group
Intervention type: OTHER
Intervention: Piper Fatigue Scale
Description: The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
Study NCT02510612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
Study NCT02807545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scoliosis Specific Exercises
Study NCT04185246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Description: NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
Study NCT04185246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
Study NCT01935934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01935934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01175993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elliptical exercise
Description: Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
Study NCT03626220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
Study NCT03626220 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT03801876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Undergo esophagectomy
Study NCT03801876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Undergo esophagectomy
Study NCT03801876 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT03801876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBT
Study NCT03801876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03801876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03801876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03801876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Folinic acid, flurouracil and oxaliplatin
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Folinic acid, flurouracil and oxaliplatin
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX regimen
Description: Capecitabine combined with oxaliplatin
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX regimen
Description: Capecitabine combined with oxaliplatin
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapy
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: Chemotherapy
Study NCT03801876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: Chemotherapy
Study NCT05620797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate loading of the implants
Description: Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
Study NCT05620797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading of the implant
Description: Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
Study NCT02510612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
Study NCT00972283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
Study NCT00972283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
Study NCT00972283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
Study NCT00972283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
Study NCT02235129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breath-holding
Study NCT04577794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: GLPG3970 powder and solvent for oral solution reconstituted prior to use.
Study NCT04577794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder and solvent for oral solution reconstituted prior to use.